Should I buy or sell NovoCure stock right now?

9 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for NovoCure in the last year. There are currently 4 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" NVCR shares. View NVCR analyst ratings or view top-rated stocks .

What is NovoCure's stock price target for 2024?

9 analysts have issued 12 month price targets for NovoCure's stock. Their NVCR share price targets range from $15.00 to $51.00. On average, they expect the company's share price to reach $31.13 in the next year. This suggests a possible upside of 157.4% from the stock's current price. View analysts price targets for NVCR or view top-rated stocks among Wall Street analysts .

How have NVCR shares performed in 2024?

NovoCure's stock was trading at $14.93 on January 1st, 2024. Since then, NVCR stock has decreased by 19.0% and is now trading at $12.09. View the best growth stocks for 2024 here .

When is NovoCure's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 2nd 2024. View our NVCR earnings forecast .

How can I listen to NovoCure's earnings call?

NovoCure will be holding an earnings conference call on Thursday, May 2nd at 8:00 AM Eastern. Interested parties can register for or listen to the call using this link .

How were NovoCure's earnings last quarter?

NovoCure Limited (NASDAQ:NVCR) announced its quarterly earnings results on Thursday, February, 22nd. The medical equipment provider reported ($0.45) earnings per share for the quarter, topping analysts' consensus estimates of ($0.53) by $0.08. The medical equipment provider earned $133.80 million during the quarter, compared to analysts' expectations of $133.80 million. NovoCure had a negative net margin of 40.65% and a negative trailing twelve-month return on equity of 51.63%. The company's revenue was up 4.2% on a year-over-year basis. During the same period in the previous year, the company posted ($0.36) EPS.

What ETFs hold NovoCure's stock?

ETFs with the largest weight of NovoCure (NASDAQ:NVCR) stock in their portfolio include Amplify BlueStar Israel Technology ETF (ITEQ) , Invesco Nasdaq Biotechnology ETF (IBBQ) and iShares U.S. Medical Devices ETF (IHI) . First Trust Nasdaq Pharmaceuticals ETF (FTXH) .

What is Asaf Danziger's approval rating as NovoCure's CEO?

17 employees have rated NovoCure Chief Executive Officer Asaf Danziger on Glassdoor.com . Asaf Danziger has an approval rating of 90% among the company's employees.

What other stocks do shareholders of NovoCure own?

Based on aggregate information from My MarketBeat watchlists, some companies that other NovoCure investors own include Chembio Diagnostics (CEMI) , Prospect Capital (PSEC) , Calumet Specialty Products Partners (CLMT) , NVIDIA (NVDA) , Two Harbors Investment (TWO) , BlackRock Capital Investment (BKCC) , Viper Energy (VNOM) , Roku (ROKU) , Salesforce (CRM) and Block (SQ) .

Who are NovoCure's major shareholders?

NovoCure's stock is owned by a number of retail and institutional investors. Top institutional shareholders include Taylor Frigon Capital Management LLC (0.12%), Counterpoint Mutual Funds LLC (0.04%) and GAMMA Investing LLC (0.00%). Insiders that own company stock include Asaf Danziger , Ashley Cordova , Ely Benaim , Frank X Leonard, Frank X Leonard , Gabriel Leung , Jeryl L Hilleman , Martin J Madden , Pritesh Shah , Todd Christopher Longsworth , Uri Weinberg , Wilhelmus Cm Groenhuysen and William F Doyle . View institutional ownership trends .

How do I buy shares of NovoCure?

Shares of NVCR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:NVCR

NovoCure (NVCR) Stock Price, News & Analysis

→ Tiny Biotech Stock Wins $75 Billion Patent (From Behind the Markets) (Ad)

Free NVCR Stock Alerts

$12.09

+0.04 (+0.33%)

(As of 04/19/2024 ET)

Compare

Today's Range: $11.89
▼
$12.32
50-Day Range: $12.05
▼
$17.29
52-Week Range: $10.87
▼
$83.60

Volume: 850,446 shs
Average Volume: 1.74 million shs
Market Capitalization: $1.30 billion

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $31.13

Get NovoCure alerts:

NovoCure MarketRank™ Stock Analysis

Analyst Rating: Moderate Buy
2.56 Rating Score
Upside/Downside: 157.4% Upside
$31.13 Price Target
Short Interest: Healthy
5.20% of Float Sold Short
Dividend Strength: N/A
Sustainability: -1.15
Upright™ Environmental Score
News Sentiment: N/A
Insider Trading: Selling Shares
$127,161 Sold Last Quarter
Proj. Earnings Growth: Decreasing
From ($1.78) to ($1.84) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.28 out of 5 stars

Medical Sector

114th out of 911 stocks

Surgical & Medical Instruments Industry

20th out of 98 stocks

4.3

Analyst's Opinion

Consensus Rating
NovoCure has received a consensus rating of Moderate Buy. The company's average rating score is 2.56, and is based on 5 buy ratings, 4 hold ratings, and no sell ratings.
Amount of Analyst Coverage
NovoCure has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

4.0

Short Interest

Percentage of Shares Shorted
5.20% of the float of NovoCure has been sold short.
Short Interest Ratio / Days to Cover
NovoCure has a short interest ratio ("days to cover") of 3.6, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in NovoCure has recently decreased by 9.57%, indicating that investor sentiment is improving significantly.

0.0

Dividend Strength

Dividend Yield
NovoCure does not currently pay a dividend.
Dividend Growth
NovoCure does not have a long track record of dividend growth.

4.5

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
NovoCure has received a 68.17% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Clinical research services for cancer", "Brain cancer medication", and "Cabozantinib" products. See details.
Environmental Sustainability
The Environmental Impact score for NovoCure is -1.15.

0.6

News and Social Media Coverage

Search Interest
8 people have searched for NVCR on MarketBeat in the last 30 days. This is an increase of 33% compared to the previous 30 days.
MarketBeat Follows
Only 6 people have added NovoCure to their MarketBeat watchlist in the last 30 days. This is a decrease of -45% compared to the previous 30 days.

2.5

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, NovoCure insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $127,161.00 in company stock.
Percentage Held by Insiders
Only 5.67% of the stock of NovoCure is held by insiders.
Percentage Held by Institutions
84.61% of the stock of NovoCure is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.0

Earnings and Valuation

Earnings Growth
Earnings for NovoCure are expected to decrease in the coming year, from ($1.78) to ($1.84) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of NovoCure is -6.20, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of NovoCure is -6.20, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
NovoCure has a P/B Ratio of 3.57. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad Behind the Markets

Tiny Biotech Stock Wins $75 Billion Patent

A little-known biotech has been quietly working on revolutionary treatments for neurodegenerative diseases. Most people have never heard of them... but those in the know have been taking notice. Jeff Bezos cut them a check for $130 million. Fidelity Biosciences for a further $217 million. They've even had several collaborative partnerships with much larger companies like Biogen, Sanofi, and Takeda.

Find out more here >>>

About NovoCure Stock (NASDAQ:NVCR)

NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, Japan, Greater China, and internationally. The company's TTFields devices include Optune Gio and Optune Lua. It also has ongoing clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. NovoCure Limited was incorporated in 2000 and is headquartered in Saint Helier, Jersey.

NVCR Stock Price History

30 days | 90 days | 365 days | Advanced Chart

NVCR Stock News Headlines

April 11, 2024 | markets.businessinsider.com

Buy Rating on NovoCure: Promising METIS Therapy and Strategic Commercial Execution

April 11, 2024 | americanbankingnews.com

NovoCure (NASDAQ:NVCR) Stock Rating Reaffirmed by Piper Sandler

April 20, 2024 | Behind the Markets (Ad)

Tiny Biotech Stock Wins $75 Billion Patent

April 5, 2024 | businesswire.com

Novocure Announces 20 Presentations On Tumor Treating Fields, Highlighting Preclinical Effects in Pancreatic Cancer and Immune Effects, at American Association for Cancer Research (AACR) Annual Meeting 2024

April 3, 2024 | markets.businessinsider.com

NovoCure (NVCR) Receives a Buy from Wells Fargo

April 1, 2024 | finance.yahoo.com

Novocure to Report First Quarter 2024 Financial Results

March 30, 2024 | fool.com

Why NovoCure Stock Soared 18.3% This Week

March 29, 2024 | markets.businessinsider.com

NovoCure’s TTFields Show Promise in METIS Study: Outperform Rating Reaffirmed with Raised Price Target

April 20, 2024 | Behind the Markets (Ad)

Tiny Biotech Stock Wins $75 Billion Patent

March 28, 2024 | fool.com

Why Novocure Stock Is Jumping Today

March 27, 2024 | seekingalpha.com

NovoCure: Sell The METIS-Inspired Rally

March 27, 2024 | markets.businessinsider.com

Nuanced Phase 3 Results Prompt Cautious Hold Rating for NovoCure’s Stock

March 27, 2024 | msn.com

Novocure's device shown to slow cancer progression in the brain in trial

March 27, 2024 | markets.businessinsider.com

Peeling Back The Layers: Exploring NovoCure Through Analyst Insights

March 27, 2024 | marketwatch.com

Novocure’s stock surges after positive results in brain-cancer trial

March 27, 2024 | markets.businessinsider.com

Novocure Shares Rise After Phase 3 METIS Trial Met Primary Endpoint

March 27, 2024 | msn.com

Novocure Stock Soars, Its Lung Cancer Electric Field Treatment Slows Progression To Brain, Data Shows

March 27, 2024 | proactiveinvestors.com

NovoCure device slows spread of lung cancer to brain in late-stage study; shares rise

March 27, 2024 | marketwatch.com

Novocure Shares Surge Premarket on Phase 3 TTFields Study

March 27, 2024 | investing.com

Novocure shares jump after trial meets primary endpoint

March 27, 2024 | msn.com

Novocure's lung cancer therapy succeeds in late-stage trial

March 27, 2024 | businesswire.com

Zai Lab Partner Novocure Announces METIS Phase 3 Clinical Trial Met Primary Endpoint, Demonstrating a Statistically Significant Extension in Time to Intracranial Progression for Patients with Brain Metastases from Non-Small Cell Lung Cancer

March 27, 2024 | businesswire.com

METIS Phase 3 Clinical Trial Met Primary Endpoint, Demonstrating a Statistically Significant Extension in Time to Intracranial Progression for Patients with Brain Metastases from Non-Small Cell Lung Cancer

March 20, 2024 | finance.yahoo.com

NVCR Dec 2025 17.500 call

March 20, 2024 | finance.yahoo.com

NVCR Jan 2026 20.000 call

March 15, 2024 | finance.yahoo.com

NVCR Apr 2024 10.000 put

March 15, 2024 | finance.yahoo.com

NVCR Apr 2024 17.500 call

See More Headlines

Receive NVCR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for NovoCure and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 2/22/2024
Today: 4/20/2024
Next Earnings (Confirmed): 5/02/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Surgical & medical instruments
Sub-Industry: N/A
Current Symbol: NASDAQ:NVCR
CUSIP: N/A
CIK: 1645113
Web: www.novocure.com
Phone: 441534756700
Fax: N/A
Employees: 1,453
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $31.13
High Stock Price Target: $51.00
Low Stock Price Target: $15.00
Potential Upside/Downside: +157.4%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.56
Research Coverage: 9 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($1.95)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-207,040,000.00
Net Margins: -40.65%
Pretax Margin: -37.65%
Return on Equity: -51.63%
Return on Assets: -17.90%

Debt

Debt-to-Equity Ratio: 1.57
Current Ratio: 5.78
Quick Ratio: 5.56

Sales & Book Value

Annual Sales: $509.34 million
Price / Sales: 2.55
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $3.39 per share
Price / Book: 3.57

Miscellaneous

Outstanding Shares: 107,610,000
Free Float: 101,505,000
Market Cap: $1.30 billion
Optionable: Optionable
Beta: 0.42

The Best High-Yield Dividend Stocks for 2024

Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.

Get This Free Report

Key Executives

Mr. William F. Doyle (Age 62)
Executive Chairman
Comp: $1.52M
Mr. Asaf Danziger (Age 58)
CEO & Director
Comp: $1.7M
Ms. Ashley Cordova (Age 45)
Chief Financial Officer
Comp: $933.39k
Mr. Wilhelmus C. M. Groenhuysen (Age 66)
Chief Operating Officer
Comp: $1.01M
Mr. Frank Leonard
Executive VP & President of Novocure Oncology
Prof. Yoram Palti M.D. (Age 86)
Ph.D., Founder & CTO
Comp: $282.51k
Dr. Moshe Giladi Ph.D. (Age 54)
Chief Science Officer
Ms. Ingrid Goldberg
VP of Investor Relations
Mr. Barak Ben Arye (Age 47)
General Counsel
Mr. Michael Puri (Age 55)
Chief Human Resources Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

NVCR Stock Analysis - Frequently Asked Questions

Should I buy or sell NovoCure stock right now?: 9 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for NovoCure in the last year. There are currently 4 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" NVCR shares.
View NVCR analyst ratings or view top-rated stocks.
What is NovoCure's stock price target for 2024?: 9 analysts have issued 12 month price targets for NovoCure's stock. Their NVCR share price targets range from $15.00 to $51.00. On average, they expect the company's share price to reach $31.13 in the next year. This suggests a possible upside of 157.4% from the stock's current price.
View analysts price targets for NVCR or view top-rated stocks among Wall Street analysts.
How have NVCR shares performed in 2024?: NovoCure's stock was trading at $14.93 on January 1st, 2024. Since then, NVCR stock has decreased by 19.0% and is now trading at $12.09.
View the best growth stocks for 2024 here.
When is NovoCure's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, May 2nd 2024.
View our NVCR earnings forecast.
How can I listen to NovoCure's earnings call?: NovoCure will be holding an earnings conference call on Thursday, May 2nd at 8:00 AM Eastern. Interested parties can register for or listen to the call using this link.
How were NovoCure's earnings last quarter?: NovoCure Limited (NASDAQ:NVCR) announced its quarterly earnings results on Thursday, February, 22nd. The medical equipment provider reported ($0.45) earnings per share for the quarter, topping analysts' consensus estimates of ($0.53) by $0.08. The medical equipment provider earned $133.80 million during the quarter, compared to analysts' expectations of $133.80 million. NovoCure had a negative net margin of 40.65% and a negative trailing twelve-month return on equity of 51.63%. The company's revenue was up 4.2% on a year-over-year basis. During the same period in the previous year, the company posted ($0.36) EPS.

What ETFs hold NovoCure's stock?: ETFs with the largest weight of NovoCure (NASDAQ:NVCR) stock in their portfolio include Amplify BlueStar Israel Technology ETF (ITEQ), Invesco Nasdaq Biotechnology ETF (IBBQ) and iShares U.S. Medical Devices ETF (IHI).First Trust Nasdaq Pharmaceuticals ETF (FTXH).
What is Asaf Danziger's approval rating as NovoCure's CEO?: 17 employees have rated NovoCure Chief Executive Officer Asaf Danziger on Glassdoor.com. Asaf Danziger has an approval rating of 90% among the company's employees.
What other stocks do shareholders of NovoCure own?: Based on aggregate information from My MarketBeat watchlists, some companies that other NovoCure investors own include Chembio Diagnostics (CEMI), Prospect Capital (PSEC), Calumet Specialty Products Partners (CLMT), NVIDIA (NVDA), Two Harbors Investment (TWO), BlackRock Capital Investment (BKCC), Viper Energy (VNOM), Roku (ROKU), Salesforce (CRM) and Block (SQ).
Who are NovoCure's major shareholders?: NovoCure's stock is owned by a number of retail and institutional investors. Top institutional shareholders include Taylor Frigon Capital Management LLC (0.12%), Counterpoint Mutual Funds LLC (0.04%) and GAMMA Investing LLC (0.00%). Insiders that own company stock include Asaf Danziger, Ashley Cordova, Ely Benaim, Frank X Leonard, Frank X Leonard, Gabriel Leung, Jeryl L Hilleman, Martin J Madden, Pritesh Shah, Todd Christopher Longsworth, Uri Weinberg, Wilhelmus Cm Groenhuysen and William F Doyle.
View institutional ownership trends.
How do I buy shares of NovoCure?: Shares of NVCR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:NVCR) was last updated on 4/20/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

NovoCure (NVCR) Stock Price, News & Analysis

NovoCure MarketRank™ Stock Analysis

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

Environmental Sustainability

News and Social Media Coverage

Search Interest

MarketBeat Follows

Company Ownership

Earnings and Valuation

About NovoCure Stock (NASDAQ:NVCR)

NVCR Stock Price History

NVCR Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Insiders & Institutions

NVCR Stock Analysis - Frequently Asked Questions

Overall MarketRank^™